For GS010, the first gene replacement therapy for vision loss in Leber Hereditary Optic Neuropathy (LHON/ND4 mutation), the recruitment has been successfully completed for the Phase I/II trial in France. For more information, click here.
Two Phase 3 trials are now being conducted in 7 sites in Europe (CHNO XV-XX in Paris France, Moorfields Eye Hospital in London UK, Ospedale Bellaria in Bologna Italy and Friedrich-Baur-Institute in Munich Germany) and in the US (Doheny Eye Institute in Los Angeles, California, Emory Eye Center in Atlanta, Georgia and Wills Eye Hospital in Philadelphia, Pennsylvania) to evaluate the efficacy of GS010 in LHON patients with an early onset of disease of less than one year as follows :
RESCUE : Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation
REVERSE : Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation
For more information on clinical trials, please contact us:
Thank you for contacting us
A representative will contact your shortly.